Predict your next investment

Corporation
INTERNET | Internet Software & Services / Health & Wellness
cb2insights.com

See what CB Insights has to offer

Founded Year

2014

Stage

Reverse Merger | IPO

Total Raised

$4.06M

Market Cap

0.25B

About CB2 Insights

CB2 Insights develops information technology (IT) solutions for the healthcare industry to maximize productivity, improve clinical workflow, and offer patient care and management. The company develops Sail Cannabis, a solution which brings medical cannabis as an alternative therapy. It offers patient care management, enhanced preparation procedures, electronic medical document transmission and verification, reporting tools and auditing measures, and monitoring tools and follow-up procedures.

CB2 Insights Headquarter Location

5045 Orbitor Drive Building 11, Suite 300

Mississauga, Ontario, L4W 4Y4,

Canada

855-874-4999

Latest CB2 Insights News

Skylight Health is one to watch in 2021, says Beacon Securities

Jan 4, 2021

Skylight Health is one to watch in 2021, says Beacon Securities There are a lot of catalysts on the horizon for Skylight Health Group ( Skylight Health Group Stock Quote, Chart, News, Analysts CSE:SHG ), according to Beacon Securities analyst Gabriel Leung, who delivered a corporate update to clients on Monday, saying with its acquisitive mindset 2021 should be quite eventful for Skylight. The former CB2 Insights, Skylight Health operates a US multi-state health network of multi-disciplinary medical clinics providing services including primary care, sub-specialty, allied health and laboratory/diagnostic testing along with telemedicine capabilities. Skylight on December 30th announced the closing of a previously announced bought deal offering of 13.8 million shares at $1.00 per for gross proceeds of $13.8 million. The company plans to use the money for M&A and general corporate purposes. “We are pleased to see the strong demand and support from this sophisticated group of investors who share our vision of working diligently, yet aggressively, to advance our company from these early growth stages with highly accretive, strategic, and profitable acquisitions,” said Prad Sekar, Co-Founder and CEO, in a press release. Skylight also announced on December 30 closing on its acquisition of Tennessee-based Perimeter Pain and Primary Care Clinic, a medical practice servicing over 12,000 patients per year with primary care, chronic pain management, interventional procedures, weight management, regenerative medicine and aesthetics, with services primarily reimbursed through private and public payors. The Cookeville, Tennessee, company generated $2.2 million in revenues and $400,000 in EBITDA in 2019, while Skylight paid $1.03 million in cash for the business. On the new financing, Leung estimated Skylight’s cash position to now be about $18 million against debt of about $900,000 and its basic shares outstanding at about 174 million. With the update, Leung has retained his “Speculative Buy” rating on Skylight but lowered his target price from $1.65 to $1.55 based on dilution from the recent financing. At press time, Leung’s target, which comes from a 12x calendar 2021 EV/Sales multiple (which is in line with its peer group, according to Leung) represented a projected 12-month return of 32 per cent. “We expect 2021 to be an exciting year for Skylight as it continues to pursue accretive acquisitions, which expand its geographic footprint and service offering. We also expect to see evidence of the company’s ability to drive revenue accretion from its existing patient roster through the introduction of insured services. Leung noted that Skylight announced five acquisitions in the fourth quarter 2020 alone. On the Perimeter acquisition, Leung said, “Perimeter is expected to leverage Skylight’s telemedicine infrastructure to provide access to patients across the State of Tennessee. Meanwhile, services offered by Perimeter will apply to Skylight’s entire patient base, which should help to increase revenue per patient over time.” For the full 2020 year, Leung is calling for Skylight to generate $13.3 million in revenue and $0.1 million in EBITDA and for 2021 he is estimating $25.4 million in revenue and $2.3 million in EBITDA. Skylight on Monday announced receipt of final approval to list on the TSX Venture, starting on January 6, 2021, under the ticker SHG. On December 31, Skylight provided a corporate overview of the past 12 months, highlighting its three financings over the year, which raised over $22 million and involving over 11 institutions in the US and Canada, along with five new clinical acquisition announcements that in aggregate add annualized revenue of about $13 million and $2.5 million in EBITDA. The company now provides care to over 135,000 patients across 15 states. “2020 has been nothing short of a transformative year for the Company,” said Sekar in a press release . “Delivering adjusted EBITDA positivity, strengthening of our balance sheet with cash and extinguishing long-term debt, and adding strong revenue and profitability growth as we exit 2020 should make all of us at Skylight and amongst our shareholders and other stakeholders feel proud and excited for the year ahead.” Skylight said it will execute against its three-pronged growth model in 2021, which involves strategic acquisition, organic growth and expansion of its subscription-based services. The company said the US healthcare market, a multi-trillion-dollar sector, is ripe for disruption and it sees more than 200 potential acquisition opportunities at any given time which would be ideal additions to Skylight. “Incremental to each acquisition, the Company employs a proven multi-disciplinary platform backed by 25-plus years of founder led clinical management expertise, to enhance the existing base of clinical revenue and broaden the offerings available within each clinic. The Company’s clinic network will offer primary care services. Additional services will be based on each population set in each region and will complement the healthcare needs of patients,” Skylight said. Since its debut at $0.70 per share on November 30, 2020, Skylight has climbed as high as $1.35 and is currently trading at $1.17.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CB2 Insights

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CB2 Insights is included in 2 Expert Collections, including Cannabis.

C

Cannabis

3,602 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

D

Digital Health

10,285 items

Companies using/incorporating digital tech into health, wellness, and life science offerings. Includes cos operating within the hc, consumer health, and life science industries + tech vendors catering to them. Excludes cos exclusively focused on fitness/sports & performance

CB2 Insights Patents

CB2 Insights has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/1/2015

12/20/2016

Capacitors, Analog circuits, Electronic design, Oscillators, Linear filters

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/1/2015

00/00/0000

Grant Date

12/20/2016

00/00/0000

Title

Subscribe to see more

Related Topics

Capacitors, Analog circuits, Electronic design, Oscillators, Linear filters

Subscribe to see more

Status

Grant

Subscribe to see more

CB2 Insights Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CB2 Insights Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.